What's in Université de Sherbrooke's pipeline?

Université de Sherbrooke has 9 drugs in our index: 6 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Université de Sherbrooke's portfolio?

Top competitors by shared drug class: University of British Columbia, Vanderbilt University Medical Center, Kasr El Aini Hospital, Oslo University Hospital, University of Minnesota.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universit-de-sherbrooke.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Université de Sherbrooke — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Université de Sherbrooke pipeline: 6 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Brand name travoprost	Brand name travoprost	marketed
Hypertonic saline 3% bolus administration	Hypertonic saline 3% bolus administration	marketed	Osmotic agent		Neurology
Generic travoprost	Generic travoprost	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor	Ophthalmology
CycloSPORINE Ophthalmic	CycloSPORINE Ophthalmic	marketed	Calcineurin inhibitor	Calcineurin	Ophthalmology
Intrathecal Morphine/Sufentanil	Intrathecal Morphine/Sufentanil	marketed	Opioid agonist	Mu-opioid receptor (μ-OR)	Pain Management
Levothyroxine supplementation	Levothyroxine supplementation	marketed
Androgen blockade + radiation therapy	Androgen blockade + radiation therapy	phase 3	Androgen receptor antagonist + radiation therapy (combination)	Androgen receptor (AR)	Oncology
Metformin, glyburide and insulin	Metformin, glyburide and insulin	phase 3	Antidiabetic combination therapy (biguanide + sulfonylurea + insulin)		Diabetes
tinidazole+fluconazole vs metronidazole+clotrimazole	tinidazole+fluconazole vs metronidazole+clotrimazole	phase 3	Nitroimidazole antibiotic, Azole antifungal		Infectious Diseases

Therapeutic area mix

Ophthalmology · 2
Diabetes · 1
Infectious Diseases · 1
Neurology · 1
Oncology · 1
Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University of British Columbia · 2 shared drug classes
Vanderbilt University Medical Center · 2 shared drug classes
Kasr El Aini Hospital · 2 shared drug classes
Oslo University Hospital · 2 shared drug classes
University of Minnesota · 2 shared drug classes
Allergan · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Albert Einstein Healthcare Network · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Université de Sherbrooke:

Cite this brief

Drug Landscape (2026). Université de Sherbrooke — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-de-sherbrooke. Accessed 2026-05-16.